ArticleFrontiers in pharmacology2026
Awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects among healthcare providers in Saudi Arabia.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobials are among the most frequently prescribed medications worldwide, yet their neurocognitive adverse effects remain underrecognized. The adverse effects range from mild symptoms to serious effects and unrecognized adverse effects may influence prescribing behaviors and inappropriate continuation or discontinuation of antimicrobial therapy. Evidence on healthcare providers' awareness, attitudes, and self-reported clinical management regarding neurocognitive risks is limited, especially in Saudi Arabia. This study aimed to evaluate healthcare providers' awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects in Saudi Arabia. Methods: A cross-sectional survey was conducted among healthcare providers in primary, secondary, and tertiary healthcare settings. A structured, self-administered questionnaire assessed awareness, attitudes, and self-reported clinical management related to neurocognitive adverse effects. Descriptive statistics and inferential analyses (Chi-square/Fisher's exact tests) were performed. Results: Among 370 participants, 41.1% reported encountering neurological or cognitive symptoms during antimicrobial therapy, most commonly confusion and agitation. Fluoroquinolones were most frequently implicated (61.9%). High awareness was observed in 31.1%, while 27.0% demonstrated low awareness. Positive attitudes toward considering neurocognitive risks were reported by 74.6%. Most providers (94.1%) reported appropriate clinical management of suspected neurocognitive adverse effects, but only 46.2% reported consistent documentation. Physicians demonstrated significantly higher awareness, more positive attitudes, and more appropriate management than other professions (p < 0.05). Conclusion: Important gaps in awareness and documentation of neurocognitive adverse effects persist among healthcare providers. Strengthening multidisciplinary education, integrating neurocognitive safety into antimicrobial stewardship programs, and improving reporting systems are essential to enhance patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.